"
Team:Stockholm/Results/BioBricks
From 2010.igem.org
(→Cell-penetrating peptides) |
(→Cell-penetrating peptides) |
||
| Line 5: | Line 5: | ||
===Low Molecular Weight Protamine (LMWP)=== | ===Low Molecular Weight Protamine (LMWP)=== | ||
| - | ''' | + | '''BBa_K38xxxx''' (Standard part) |
Sequence (fasta) | Sequence (fasta) | ||
| - | ''' | + | '''BBa_K38xxxx''' (N-part) |
Sequence (fasta) | Sequence (fasta) | ||
| Line 15: | Line 15: | ||
===Transportan 10 (Tra10)=== | ===Transportan 10 (Tra10)=== | ||
| - | ''' | + | '''BBa_K38xxxx''' (Standard part) |
Sequence (fasta) | Sequence (fasta) | ||
| - | ''' | + | '''BBa_K38xxxx''' (N-part) |
Sequence (fasta) | Sequence (fasta) | ||
| Line 25: | Line 25: | ||
===''Trans''-Activating Transcriptional Activator (TAT)=== | ===''Trans''-Activating Transcriptional Activator (TAT)=== | ||
| - | + | TAT is a cell-penetrating peptide that may be used in fusions with full-length proteins to create transduction proteins with the ability to permeate the lipid bilayer of various cell types. | |
| - | : | + | Purified full-length TAT fusion proteins expressed in ''Escherichia coli'' have been shown to successfully translocate into several human cell types, including all cells found in whole blood, as well as bone marrow stem cells and osteoblasts, while still retaining the fused protein's activity ([http://www.ncbi.nlm.nih.gov/pubmed/9846587 Nagahara ''et al.'' 1998]). The mechanism for transduction over the bilipid membrane is still a matter of debate, but has been suggested to occur through macropinocytosis, a specialized form of endocytosis ([http://www.ncbi.nlm.nih.gov/pubmed/17913584 Gump and Dowdy, 2007]). |
| - | + | ====Standard part==== | |
| - | : | + | '''Part name:''' TAT cell-penetrating peptide<br /> |
| + | '''Registry name:''' [http://partsregistry.org/Part:BBa_K380000 BBa_K380000]<br /> | ||
| + | '''Sequencing result:''' <span style="color:green;">Verified</span> (fasta)<br /> | ||
| + | '''Functionality:''' <span style="color:red;">Not verified</span> | ||
| + | |||
| + | ====Standard part==== | ||
| + | |||
| + | '''Part name:''' N-part TAT cell-penetrating peptide<br /> | ||
| + | '''Registry name:''' [http://partsregistry.org/Part:BBa_K380000 BBa_K380001]<br /> | ||
| + | '''Sequencing result:''' <span style="color:green;">Verified</span> (fasta)<br /> | ||
| + | '''Functionality:''' <span style="color:red;">Not verified</span> | ||
==Proteins== | ==Proteins== | ||
Revision as of 23:25, 23 October 2010
| Home | Project Idea | Lab Work | Results | Modelling | Team | Follow us on  and 
| 2010.igem.org 
|
Contents |
Cell-penetrating peptides
Low Molecular Weight Protamine (LMWP)
BBa_K38xxxx (Standard part)
Sequence (fasta)
BBa_K38xxxx (N-part)
Sequence (fasta)
Transportan 10 (Tra10)
BBa_K38xxxx (Standard part)
Sequence (fasta)
BBa_K38xxxx (N-part)
Sequence (fasta)
Trans-Activating Transcriptional Activator (TAT)
TAT is a cell-penetrating peptide that may be used in fusions with full-length proteins to create transduction proteins with the ability to permeate the lipid bilayer of various cell types.
Purified full-length TAT fusion proteins expressed in Escherichia coli have been shown to successfully translocate into several human cell types, including all cells found in whole blood, as well as bone marrow stem cells and osteoblasts, while still retaining the fused protein's activity ([http://www.ncbi.nlm.nih.gov/pubmed/9846587 Nagahara et al. 1998]). The mechanism for transduction over the bilipid membrane is still a matter of debate, but has been suggested to occur through macropinocytosis, a specialized form of endocytosis ([http://www.ncbi.nlm.nih.gov/pubmed/17913584 Gump and Dowdy, 2007]).
Standard part
Part name: TAT cell-penetrating peptide
Registry name: [http://partsregistry.org/Part:BBa_K380000 BBa_K380000]
Sequencing result: Verified (fasta)
Functionality: Not verified
Standard part
Part name: N-part TAT cell-penetrating peptide
Registry name: [http://partsregistry.org/Part:BBa_K380000 BBa_K380001]
Sequencing result: Verified (fasta)
Functionality: Not verified
